First-Line Systemic Treatment for Advanced Progressive Medullary Thyroid Cancer

When medullary thyroid cancer presents with significant tumor burden and symptomatic or progressive metastatic disease, systemic therapy becomes the primary treatment strategy. A structured first-line approach exists for this clinical scenario.

Clinical Scenario

This protocol is intended for patients with advanced medullary thyroid cancer whose disease is progressive or symptomatic at the metastatic stage, where systemic intervention is indicated per standard response criteria.

Treatment Approach

First-line management involves single-agent systemic therapy with a targeted tyrosine kinase inhibitor. The full protocol specifies which agents qualify, their selection criteria, and the complete structured regimen.

Agent selection, dosing, and the full clinical algorithm are available in the complete protocol below.

Instant Access to Structured Evidence-Based Regimens

References

In patients with significant tumor burden and symptomatic or progressive metastatic disease according to RECIST treatment with TKIs targeting both RET and VEGFR tyrosine kinases should be considered as systemic therapy.
The TKIs vandetanib or cabozantinib can be used as single-agent first-line systemic therapy in patients with advanced progressive MTC.

DOI: 10.1089/thy.2014.0335

View source ↗